Navigation Links
ATS Medical Announces Participation in 45th Annual Society of Thoracic Surgeons Meeting
Date:1/22/2009

MINNEAPOLIS, Jan. 22 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced its participation in the 45th Annual Meeting of the Society of Thoracic Surgeons (STS) and related company-sponsored events. The meeting runs January 24-28, 2009, in San Francisco, California, and serves as one of the year's key gatherings of cardiovascular surgeons from around the world.

(Photo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

ATS Medical continues to expand its cardiac surgery product portfolio, and this meeting provides an excellent opportunity to display its array of offerings for heart valve therapy and surgical ablation of cardiac arrhythmias. The ATS CryoMaze(TM) system for surgical cryoablation will be prominently featured. Surgical treatment of cardiac arrhythmias is a topic of great interest for surgeons and increasing numbers find the ATS CryoMaze system to be their product of choice. ATS is sponsoring "Frontiers in Cryoablation," a symposium designed to provide a unique forum for sharing experiences among physician attendees. ATS Medical's Cryoablation Scientific Advisory Board members will lead the open discussion in a question and answer format. The symposium will be held on Sunday, January 25th at 7:00 pm at the Marriott San Francisco.

The ATS exhibit will also focus on the company's flagship ATS Open Pivot(R) mechanical heart valve franchise, including its newest iteration, the ATS Open Pivot(R) AP360(TM), as well as its newly-approved ATS 3f(R) Aortic Bioprosthesis tissue valve. The AP360(TM) valve's unique open pivot design results in exceptional performance and a low risk profile while the A
'/>"/>

SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Turner Selected to Construct Replacement Hospital for University Medical Center at Princeton
2. Nurses Often Left Out of Medical Error Talks
3. Midwest Pulmonary and Critical Care Associates Will Join Aurora Medical Group
4. B. Braun Medical Inc. Launches Home Infusion Therapy Web Site
5. Natural TMJ Relief(R) Gains Momentum in the Medical Marketplace
6. China Medical Technologies Announces the Receipt of SFDA Approval for Two of its FISH Probes and the Approval for the Hi-Tech Enterprise Status for its PRC Subsidiaries
7. Medical Management Corporation Updates Medical Billing Services
8. University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing
9. USC awarded $22.2M NIH national biomedical informatics infrastructure coordinating center contract
10. Houston Northwest Medical Center Is One of Two Hospitals in Texas Named A Mentor Hospital for Heart Attack
11. American Heart Association 2008 Wrap-Up Report: Top Research Advances Include Studies That Influence Medical Care, Apply Science To Real World Communities
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 1YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 3OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 1OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 2Fitness Might Limit Strokes Impact 51687 1Fitness Might Limit Strokes Impact 51687 2